M
Margaret von Mehren
Researcher at Fox Chase Cancer Center
Publications - 235
Citations - 25908
Margaret von Mehren is an academic researcher from Fox Chase Cancer Center. The author has contributed to research in topics: GiST & Imatinib mesylate. The author has an hindex of 57, co-authored 209 publications receiving 22577 citations. Previous affiliations of Margaret von Mehren include Oregon Health & Science University & University of Helsinki.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D. Demetri,Margaret von Mehren,Charles D. Blanke,Annick D. Van den Abbeele,Burton L. Eisenberg,Peter J. Roberts,Michael Heinrich,David A. Tuveson,Samuel Singer,Milos J. Janicek,Jonathan A. Fletcher,Stuart G. Silverman,Sandra Silberman,Renaud Capdeville,Beate Kiese,Bin Peng,Sasa Dimitrijevic,Brian J. Druker,Christopher L. Corless,Christopher D.M. Fletcher,Heikki Joensuu +20 more
TL;DR: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor, indicating that inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinalStromal tumors, which resist conventional chemotherapy.
Journal ArticleDOI
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Michael Heinrich,Christopher L. Corless,George D. Demetri,Charles D. Blanke,Margaret von Mehren,Heikki Joensuu,Laura McGreevey,Chang Jie Chen,Annick D. Van den Abbeele,Brian J. Druker,Beate Kiese,Burton L. Eisenberg,Peter J. Roberts,Samuel Singer,Christopher D.M. Fletcher,Sandra Silberman,Sasa Dimitrijevic,Jonathan A. Fletcher +17 more
TL;DR: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib.
Journal ArticleDOI
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Ronald P. DeMatteo,Karla V. Ballman,Cristina R. Antonescu,Robert G. Maki,Peter W.T. Pisters,George D. Demetri,Martin E. Blackstein,Charles D. Blanke,Margaret von Mehren,Murray F. Brennan,Shreyaskumar Patel,Martin D. McCarter,Jonathan Polikoff,Benjamin R. Tan,Kouros Owzar +14 more
TL;DR: Adjuvant imatinib therapy is safe and seems to improve recurrence-free survival compared with placebo after the resection of primary gastrointestinal stromal tumour.
Journal ArticleDOI
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri,Peter Reichardt,Yoon-Koo Kang,Jean-Yves Blay,Piotr Rutkowski,Hans Gelderblom,Peter Hohenberger,Michael F. Leahy,Margaret von Mehren,Heikki Joensuu,Giuseppe Badalamenti,Martin E. Blackstein,Axel Le Cesne,Patrick Schöffski,Robert G. Maki,Sebastian Bauer,Binh Bui Nguyen,Jianming Xu,Toshirou Nishida,John Chung,Christian Kappeler,Iris Kuss,D. Laurent,Paolo G. Casali +23 more
TL;DR: The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on standard treatments.
Journal ArticleDOI
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors
George D. Demetri,Margaret von Mehren,Cristina R. Antonescu,Ronald P. DeMatteo,Kristen N. Ganjoo,Robert G. Maki,Peter W.T. Pisters,Chandrajit P. Raut,Richard F. Riedel,Scott M. Schuetze,Hema Sundar,Jonathan C. Trent,Jeffrey D. Wayne +12 more
TL;DR: The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate.